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Abstract 
 
Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2           
virus. It was first identified in Wuhan, China, and has since spread causing a global               
pandemic. Various studies have been performed to understand the molecular mechanisms           
of viral infection for predicting drug repurposing candidates. However, such information is            
spread across many publications and it is very time-consuming to access, integrate, explore,             
and exploit. We developed CoVex, the first interactive online platform for SARS-CoV-2 and             
SARS-CoV-1 host interactome exploration and drug (target) identification. CoVex integrates          
1) experimentally validated virus-human protein interactions, 2) human protein-protein         
interactions and 3) drug-target interactions. The web interface allows user-friendly visual           
exploration of the virus-host interactome and implements systems medicine algorithms for           
network-based prediction of drugs. Thus, CoVex is an important resource, not only to             
understand the molecular mechanisms involved in SARS-CoV-2 and SARS-CoV-1         
pathogenicity, but also in clinical research for the identification and prioritization of candidate             
therapeutics. We apply CoVex to investigate recent hypotheses on a systems biology level             
and to systematically explore the molecular mechanisms driving the virus’ life cycle.            
Furthermore, we extract and discuss drug repurposing candidates involved in these           
mechanisms. CoVex renders COVID-19 drug research systems-medicine-ready by giving         
the scientific community direct access to network medicine algorithms integrating          
virus-host-drug interactions. It is available at ​https://exbio.wzw.tum.de/covex/​. 
 
 Introduction 
 
Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by SARS-CoV-2          
(severe acute respiratory syndrome coronavirus 2). It was first identified in Wuhan, China             
and has spread causing an ongoing pandemic ​1 with globally 2.4 million confirmed cases              
and 167 thousand deaths as of April 20, 2020. 
 
Our insights into SARS-CoV-2 infection mechanisms are limited and clinical therapy has            
largely focused on treating critical symptoms. Therefore, the current pandemic requires fast            
and freely accessible knowledge to accelerate the development of vaccines, treatments and            
diagnostic tests. Research data has been collected in several online platforms such as, the              
COVID-19 Open Research Dataset and the Dimensions COVID-19 collection ​2,3​. In addition,            
existing databases that collect virus information have responded by integrating new           
SARS-CoV-2 research ​4,5​.  
 
As vaccine and drug development may take years, drug repurposing is a potent approach              
that offers new therapeutic options through the identification of alternative uses of already             
approved drugs ​6​. These drugs have previously undergone clinical and safety trials and,             
hence, accelerate drug development timelines from a decade to a few years or months. Due               
to the COVID-19 pandemic, numerous research groups around the world have been joining             
their efforts to identify drugs that can be repurposed to effectively treat COVID-19.             
Numerous drugs are already part of clinical trials, including remdesivir (a less effective ebola              
drug), Chloroquine, Hydroxychloroquine (antimalarial drugs), Tocilizumab (rheumatoid       
arthritis drug), Favipiravir (influenza drug), and Kaletra (a combination of Lopinavir and            
Ritonavir for treating human immunodeficiency virus HIV-1) ​7​. 
 
Computational systems and network medicine approaches offer a methodological toolbox          
required to understand molecular virus-host-drug mechanisms and to predict novel drug           
targets to attack them ​8,9​. Few studies on these mechanisms in SARS-CoV-2 exist. Gordon              
et al. applied affinity purification-mass spectrometry (AP-MS) to reconstruct the          
SARS-CoV-2-human protein-protein interaction (PPI) network and subsequently employed a         
chemoinformatics approach to identify potential drugs for repurposing ​10​. The data generated            
from that study is a major advancement in understanding SARS-CoV-2 infection. However,            
to identify drug candidates, the study mainly considered the direct interactors of the human              
proteins as putative targets and thus did not take into account the network context of the                
human interactome. However, viral interactions with human proteins have cascading effects           
in the human interactome, where key proteins necessary for the viral replication cycle are              
only indirectly affected. Therefore, downstream host proteins may be additional promising           
targets for therapeutic intervention but require thorough data integration and mining to be             
identified (see Supplementary Material for details). Figure 1 illustrates the concept of            
systems medicine-based drug repurposing specifically for SARS-CoV-2. 
 
Gysi ​et al. integrated the experimentally validated SARS-CoV-2 virus-host interactions with           
the human interactome and investigated co-morbidity and differences of virus-host          
 interactions across 56 tissues ​11​. Furthermore, network medicine analysis was applied to            
compile a list of drug repurposing candidates that target also indirectly affected proteins in              
the human interactome. However, the combined number of virus-host, host-host and           
drug-target interactions goes into the millions such that purely algorithmic approaches to            
discovering new drug targets and drug repurposing candidates produces a large number of             
results, many of which lack mechanistic specificity and, hence, are not useful. Thus, to make               
their results accessible, Gysi ​et al. worked closely together with clinical experts to narrow              
down the number of predicted repurposable drugs.  
 
 
Figure 1​ ​- The SARS-CoV-2 life cycle and the CoVex systems medicine approach of 
drug repurposing.​ Most antiviral drugs (grey) target the virus proteins or their direct host 
interactor proteins to inhibit different stages of the viral life cycle. Our rationale, however, is 
that viral interactions with human host proteins have a cascading effect to hijack and control 
key proteins necessary for the virus’ life cycle. We aim to identify repurposable drug 
candidates (green) targeting these key host modulators to interfere with virus replication and 
disease progression following infection. Besides an increased antiviral drug repertoire, 
targeting host proteins would make it more difficult for the virus (population) to develop 
resistance mutations. 
 
 In order to allow for the interactive integration of expert knowledge about virus replication,              
immune-related biological processes or drug mechanisms, we have developed the          
interactive systems and network medicine platform CoVex (CoronaVirus Explorer). It          
integrates experimental virus-human interaction data for SARS-CoV-2 and SARS-CoV-1 with          
the human interactome as well as drug information to predict novel drug (target) candidates,              
and it offers biomedical and clinical researchers interactive and user-friendly access to            
network medicine algorithms for advanced data mining and hypothesis testing. CoVex           
follows a human-in-the-loop paradigm and provides an intuitive visualization of virus-host           
interactions, drug targets, and drugs to enable researchers to examine molecular           
mechanisms that can be targeted using repurposed drugs. CoVex offers two main actions             
for which several network medicine algorithms are available: Given a list of user-selected             
human host proteins, viral proteins, or drugs (referred to as seeds), users can (1) search the                
human interactome for viable drug targets and (2) identify repurposable drug candidates. In             
a typical work-flow, these two actions are combined, i.e. starting from a selection of virus or                
virus-interacting proteins, users mine the interactome for suitable drug targets for which, in             
turn, suitable drugs are identified. Additionally, users can leverage expert knowledge by            
uploading a list of proteins or drugs of interest as seeds to guide the analysis. Such seeds                 
could, for instance, be a list of differentially expressed genes, a list of proteins related to a                 
molecular mechanism of interest, or a set of drugs known to be effective. 
 
The remainder of this paper is structured as follows: In the methods section, we first describe                
the datasets and integration strategy used in CoVex. Next, we introduce the rationales of the               
systems and network medicine algorithms implemented in CoVex, and briefly describe the            
overall architecture of the platform. In the results section, we show several application             
examples to illustrate the flexibility and typical use cases of CoVex. Finally, we will discuss               
opportunities and limitations in using CoVex for COVID-19 research. 
 
CoVex opens up the systems medicine toolbox for the entire infectious disease research             
community by providing an easy-to-use web tool enriched with novel algorithms. This allows             
specialists from different fields to bring in expert knowledge to identify the most promising              
drug targets and drug repurposing candidates for developing effective therapies. We like to             
stress that the CoVex platform can and will be adopted and extended to allow exploring               
other viral-host-drug interactomes, e.g. with MERS (Middle East Respiratory Syndrome),          
Zika, dengue and influenza viruses, thereby increasing preparedness for similar future           
events. 
Methods 
Data Integration 
 
We integrated virus-host interaction data from several sources. We obtained SARS-CoV-2           
affinity purification-mass spectrometry (AP-MS) data reported by Gordon ​et al​.​10 containing           
332 high-confidence virus-host interactions for 27 SARS-CoV-2 proteins​10​, as well as           
SARS-CoV-1 interactions from VirHostNet ​4 (24 interactions), and Pfefferle ​et al. ​12 (113             
interactions existing in our interactome). Human PPIs were obtained from the integrated            
interactions database (IID) ​13 filtered based on experimental validation. The resulting           
 interactome consists of 17,666 proteins connected via 329,215 interactions. Drug-target          
associations were obtained from ChEMBL (2020-03) ​14​, DrugBank (v.5.1.5) ​15​, DrugCentral           
(2018-08-26) ​16​, Target Therapeutic Database (2019-07-14) ​17​, Guide To Pharmacology          
(2020-01; only approved drugs) ​18​, PharmGKB (downloaded 2020-04) ​19​, and BindingDB           
(2019-08-12) ​20​. Where applicable, we considered drugs that have binding affinity values            
(EC50, IC50, Kd, and Ki) less than 10 ​μ​M ​21,22​. Only drugs that were mappable to DrugBank                 
IDs and targeting host proteins were included in the network. Drugs currently undergoing             
clinical trials and mappable to DrugBank IDs (as of April 4​th 2020) for the treatment of                
COVID-19 were collected from ClinicalTrials.gov (​www.ClinicalTrials.gov​) ​23​, the EU Clinical          
Trials Register (​www.clinicaltrialsregister.eu​) and the International Clinical Trials Registry         
Platform (​www.who.int/ictrp/​). In total, we have 6,861 drugs (69 in clinical trials) and 52,860              
drug-target associations integrated in our network. 
 
Systems medicine algorithms for drug repurposing prediction 
 
The general idea of CoVex is to provide researchers and clinicians with a tool to visually                
explore druggable molecular mechanisms that drive the interactions between virus and host.            
To this end, the integrated virus-human-drug interactions form molecular networks that are            
modeled as graphs with nodes as proteins or drugs, and edges referring to interactions              
between them. The goal of CoVex is to explore this network while allowing for the               
exploitation of expert knowledge. Starting with a selected set of (usually) hypothesis-driven            
seeds (virus proteins, human proteins, or drugs), the goal is to first identify subnetworks              
connecting these seeds and, subsequently, to identify drug repurposing candidates          
associated with these mechanisms. A vast number of methods have been reported in the              
literature for identifying subnetworks ​24​. In CoVex, we have integrated several algorithms            
(including a dedicated, new development) with different underlying paradigms to provide           
specific exploration options to various particular medical, therapeutic, and research          
questions and hypotheses. CoVex, thus, allows users to choose among the following            
approaches in the “advanced analysis” procedures. 
 
Degree centrality is the simplest conceivable centrality measure and ranks proteins or            
drugs interacting with the seeds by their node degree, i.e. the number of interactions. Thus,               
this algorithm yields subnetworks in which seed-connected proteins and/or drugs are           
preferentially selected if they interact with many other proteins in the network. The only              
user-selected parameter is the result size, i.e. how many of the top-ranked proteins or drugs               
are included. Notably, centrality measures in CoVex can be used for detecting drug targets              
and for identifying promising drugs. 
 
Closeness centrality is a node centrality measure that ranks the nodes in a network based               
on the lengths of their shortest paths to all other nodes in the network. The rationale behind                 
this algorithm is to preferentially select proteins and/or drugs that are a short distance from               
all other proteins in the network and are thus of central importance. In CoVex, we use a                 
modified version suggested by Kacprowski ​et al.​, where only the shortest paths to a set of                
selected seed nodes are considered ​25​. The only algorithm-specific, user-selected parameter           
is the result size. 
 
 TrustRank: ​TrustRank is conceptually similar to closeness centrality but additionally          
considers the importance of the seed nodes themselves. In other words, TrustRank ranks             
nodes in a network based on how well they are connected to a (trusted) set of seed nodes ​26​.                   
It is a variant of Google’s PageRank algorithm, where “trust” is iteratively propagated from              
seed nodes to neighboring nodes using the network structure. The node centralities are             
initialized by assigning uniform probabilities to all seeds and zero probabilities to all             
non-seed nodes. In CoVex, the TrustRank algorithm can be run starting from a user-defined              
set of (trusted) seed proteins to obtain a ranked list of proteins in the PPI network that could                  
be prioritized as putative drug targets. Similarly, TrustRank can be executed on the joint              
protein-drug interactome to identify drug repurposing candidates. User-selected parameters         
include the result size and the damping factor (range 0 to 1), which controls how fast “trust”                 
is propagated through the network. A small damping factor results in a conservative behavior              
of the algorithm (nodes close to the seeds receive much higher scores than distant ones),               
while a large damping factor makes its behavior more explorative. 
 
Multi-Steiner tree​: ​The Steiner tree problem is a classical combinatorial optimization           
problem. It aims at finding a subgraph of minimum cost connecting a given set of seed                
nodes. For CoVex, we have developed a novel method (weighted multi-Steiner tree) which             
computes approximate weighted multiple Steiner trees and connects them to one           
subnetwork. The user can select the set of proteins of interest and extract sub-network(s)              
that connect the selected seed proteins as candidate mechanism(s) involved in COVID-19            
progression. In this mechanistic subnetwork(s), we can then extract essential proteins and,            
thus, the most promising drug targets and repurposable drugs for COVID-19. User-selected            
parameters include the number of Steiner trees to be merged as well as the tolerance               
towards accepting more expensive subnetworks (for speeding up the approximation          
algorithm; details in the Supplementary Material). 
 
KeyPathwayMiner ​is a network enrichment tool that identifies condition-specific         
subnetworks (key pathways) ​27​. In CoVex, we utilize the KeyPathwayMiner web service to             
extract a maximally connected subnetwork starting from a user-defined set of proteins of             
interest (seeds). The only user-selected parameter is K, which represents the number of             
permitted exception nodes, i.e. proteins that were not part of the seed proteins but serve to                
connect them. Since these proteins act as bridges, these may represent key proteins             
participating in the dysregulated subnetwork even though they are not directly targeted by             
the virus and are therefore promising candidates for intervention. In its current            
implementation exception nodes will only be added if they indeed possess a bridging             
characteristic and will not be shown otherwise. 
 
Hub penalty: ​Irrespective of the network analysis method used, the extracted solutions have             
a higher intrinsic probability to contain high-degree nodes (hubs), i.e. proteins that have a              
large number of interactions. While these proteins are key players in the human interactome,              
they are not necessarily suitable drug targets as perturbing them might lead to severe              
unintended side-effects. To mitigate this bias, users can either select an upper bound to filter               
out high-degree nodes or, alternatively, penalize high degree nodes by incorporating the            
degree of neighboring nodes as edge weights in the optimization. For the latter, values              
between 0 and 1 can be selected, where higher values correspond to a higher penalty. Both                
 options are available in advanced analyses for all methods except for degree centrality,             
because its rationale is to identify hubs, and KeyPathwayMiner, which conceptually does not             
allow for weighted subnetwork extraction. 
 
Implementation 
 
CoVex consists of five components: (i) Data is stored in a PostgreSQL database (v. 12.2). (ii)                
The backend is implemented using the Django web framework (v. 3.0.5) with Python (v. 3.6)               
and the Django REST framework (v. 3.11.0) to build the web API. (iii) The network               
algorithms (except KeyPathwayMiner) are implemented with graph-tool (v. 2.3.1) ​28​. (iv)           
Background task processing is implemented using Redis Queue (RQ, v. 1.3.0) and the             
in-memory database Redis (v. 3.4.1). Django enqueues the jobs and RQ processes them in              
the background while Redis functions as a broker between Django and RQ. (v) The frontend               
is implemented in Angular (v. 9.0.2) and utilizes the JavaScript libraries vis-data (v. 6.5.1)              
and vis-network (v.7.4.2) for network visualization. 
 
 
Figure 2 - The CoVex online platform.​ The network view (middle) shows drug candidates 
(green nodes) that were found using closeness centrality on a set of proteins (blue nodes) 
which resulted from a multi-Steiner tree computation with all viral proteins as seeds (not 
shown here). Therefore, drugs targeting these seeds might be able to interrupt the viral life 
cycle progression. 
 
Results 
 
The main result is the CoVex platform itself, which renders drug repurposing research             
systems-medicine-ready. In the following, we first describe how the platform’s user interface            
 provides the full feature spectrum of CoVex to clinicians and scientists. Afterwards, we             
demonstrate the use of CoVex in four different application scenarios starting with four             
hypotheses and ending with different drug repurposing candidates as well as a short             
discussion on how to prioritize them. 
 
The CoVex platform 
 
Figure 2 shows the CoVex web interface. To find potential drugs, the “Quick Start” analysis               
will produce a multi-Steiner tree, which considers all viral proteins as seeds and adds a small                
number of host proteins to connect them. Subsequently, drugs directly targeting these            
proteins are selected via closeness centrality. After the computation has finished, a click on              
the corresponding task opens the analysis results, consisting of a table view of drugs and               
proteins, a visualization of the protein-protein and drug-protein interactions, and a list of             
parameters used for the analysis. In the “Simple Analysis” panel, users can select seed              
proteins manually and search for drugs targeting them. In the “Advanced Analysis” panel,             
users can choose from a list of network medicine algorithms (see Methods and             
Supplementary Material for details) to discover drug targets or drug repurposing candidates.            
An enrichment analysis of the identified drug target proteins may be performed with             
g:Profiler ​29​. 
 
 
Figure 3 - CoVex application scenarios.​ Depending on the starting hypothesis, dedicated 
systems medicine algorithms will propagate from selected seeds to connect drugs with viral 
proteins using host proteins as proxies. Essentially, four different strategies apply: (a) 
Starting with viral proteins, one can identify drugs targeting host proteins that connect the 
viral seeds. (b) Starting with a set of proteins of interest as proxies, we identify pathways 
connecting them to (selected or all) viral proteins. Subsequently, we identify drugs targeting 
this mechanism. (c) Starting with a set of drugs of interest, one may find pathways to 
(selected or all) viral proteins extracting a potentially druggable host mechanism. (d) 
Hypothesis-driven, hybrid approach with seeds in different levels to be connected for 
druggable mechanism extraction. Boxes with light blue background indicate the typical 
starting points in the respective application scenario. 
  
Application scenarios 
 
The utility of CoVex and its integrated systems medicine approaches is outlined in the              
following four scenarios. More details on each can be found in the Supplementary Material. 
 
 
Figure 4 - Drug-protein-protein interaction network obtained using the viral proteins E, 
M and Spike with multi-Steiner tree followed by closeness centrality.​ Blue nodes are 
protein targets. Green nodes are approved drugs and orange nodes are non-approved 
drugs. Lines represent the interactions between proteins and drugs. Note that some ACE 
inhibitor drugs have been identified, such as Ramipril, Captopril, Perindopril and Enalaprilat 
targeting the BDKRB1 protein, which are currently being evaluated in clinical trials. 
 
Scenario a. Starting from a selection of viral proteins, we use the PPI network to identify the                 
biological mechanism or pathway utilized by the virus. As an example, we consider the viral               
proteins E, M and Spike, which constitute the external structure of the virus and thus               
mediate entry into the host cells during the infection process ​30,31​. We select the interactors of                
these viral proteins reported for SARS-CoV-2 and use the multi-Steiner tree algorithm to             
uncover the biological pathway involved. The resulting network (Figure 4) yields 26 new             
potential drug targets, including the Bradykinin receptor B1 (BDKRB1). Subsequently, we           
use closeness centrality to find drugs affecting this pathway. Notably, we identify 6 relevant              
drugs that target BDKRB1: Ramipril, Captopril, Perindopril and Enalaprilat (approved), which           
belong to the Angiotensin Converting Enzyme (ACE) inhibitor class ​32​; Icatibant, an            
antagonist of the Bradykinin receptor B2 ​33​; and bradykinin, a non-approved drug which is              
degraded by the ACE ​34​. Furthermore, to understand the relationship between BDKRB1 and             
two proteins known to participate in the entry of the virus (Angiotensin Converting Enzyme 2,               
ACE2 and Transmembrane protease serine 2​, ​TMPRSS2) ​35​, we use the “custom proteins”             
option available in CoVex. We find that Kininogen 1 (KNG1) and Angiotensin (AGT) proteins              
connect BDKRB1 with ACE2. These 4 proteins are functionally related through the            
 Renin-Angiotensin System, which is targeted by ACE inhibitors        
(​www.wikipathways.org/instance/WP554​). In summary, CoVex identifies the protein       
BDKRB1, which appears to play a role in SARS-CoV-2 host cell entry and can be targeted                
by several ACE inhibitors widely used in clinical trials to treat COVID-19. It should be noted                
that the ACE2 protein is not present in the set of seeds used to start the analysis.                 
Nevertheless, CoVex is capable of identifying the pathway and new protein targets            
functionally related to ACE2 (Figure 4). 
 
Scenario b. Starting from both viral proteins and a list of proteins of interest, we can use                 
CoVex to identify a connecting pathway or biological mechanisms that can be targeted by              
drugs. In this scenario, we are specifically interested in viral proteins that suppress host              
immunity and the corresponding host immune response pathways. First, we select the viral             
proteins ORF7a and ORF3a, which are potentially involved in innate immune response and             
apoptosis as discussed in Gordon ​et al. (2020) ​10​. Next, we compile a list of proteins of                 
interest based on the differentially expressed genes (DEGs) from the study by Blanco-Melo             
et al. (2020) ​36 lung epithelial cells were infected with the SARS-CoV-2 virus, leading to               
altered expression of immunity-related genes to combat the viral infection. We consider            
DEGs known to be associated with the host pathway involving infection with the Herpes              
simplex virus (HSV), another viral pathogen. These genes include ​IFIH1​, ​OAS1​, ​STAT1​,            
DDX58​, ​OAS2​, ​OAS3​, ​IRF7​, ​EIF2AK2​, ​IFIT1​, and ​IRF9​. The selected viral proteins and             
DEGs (converted to Uniprot ids) were used as seeds for the multi-Steinert tree algorithm to               
extract a potential immune-related mechanism. As expected, the resulting subnetwork          
reveals that the viral proteins are close to the DEGs in the host PPI network. Closeness                
centrality analysis assigned a high rank to Tofacitinib and Ruxolitinib, which are currently             
being assessed in clinical trials. Tofacitinib and Ruxolitinib exert immunomodulatory effects           
as Janus kinase (Jak) inhibitors ​37,38​. Thus, administration with these drugs may mitigate             
immune-mediated ​lung ​injury and reduce functional deterioration caused by an           
over-amplified host inflammatory response. This could be especially important in later stages            
of the disease to prevent an overreaction of the body’s immune system and, hence, may               
further prevent the need for mechanical ventilation in patients suffering from severe            
COVID-19. Other drugs that target this subnetwork include Masitinib, Erlotinib, and           
Sorafenib, which could be further examined in downstream analyses. In a similar manner,             
users may provide a custom list of proteins as seeds to hunt for drugs that can target a                  
putative  mechanism of interest. 
 
Scenario c. Starting with a set of drugs of interest, we can follow a top-down approach to                 
extract potential host mechanisms and additional drugs targeting the proteins participating in            
these mechanisms. As an example, we identify 69 drugs currently in clinical trials for              
COVID-19 and group them based on their Anatomical Therapeutic Chemical (ATC)           
classification (Suppl. Table S5)​39​. We focus on drugs from the immunostimulants class (L03)             
and their target proteins as starting seeds. We further select the interactors of the              
immune-related viral proteins ORF9B, ORF6, ORF3B, and ORF3A​10 as end-point seeds. By            
applying the multi-Steiner tree algorithm, we discover pathways of interacting proteins that            
connect the selected drugs (and their target proteins) with the selected viral proteins.             
Among these connector proteins, we find five genes associated with cytokine signaling in the              
immune system according to Reactome Pathways CSF2, NRG1, NUP188, PTPN18,          
 SOCS1)​40​. Notably, CSF2 is enriched in lung, pancreas and immune cells           
(​www.proteinatlas.org/ENSG00000164400-CSF2​)​41 and can be inhibited by ​KB002       
(​DB05194), which is an investigational drug and an engineered human monoclonal antibody            
treatment for inflammatory and autoimmune processes​15​. In summary, with CoVex, we found            
a new drug target which may play a key role in the host immune response during viral                 
infection. We also identified a new drug candidate for COVID-19, as it targets the proteins               
involved in the pathogenic mechanisms triggered by ORF3A, ORF3B, ORF6, and ORF9B            
viral proteins. 
 
Scenario d. Starting from a hypothesis-driven mixed selection of viral and host proteins as              
well as drugs, we seek to utilize PPIs to identify a full mechanism or pathway and to suggest                  
additional drug candidates. As an application case, we follow up on a recently published              
hypothesis by Liu and Abrahams concerning the putative interference of SARS-CoV-2 with            
the formation of hemoglobin in erythrocytes ​42,43​. Essentially, the virus is believed to interfere              
with heme formation causing symptoms of hypoxia. Liu and Abrahams hypothesize that this             
would also explain why Chloroquine and Favipiravir are effective drugs, as they may prevent              
the viral proteins from competing with iron for the porphyrin in hemoglobin (NSP1-16,             
ORF3a, ORF10, and ORF8 targeted by Chloroquine as well as ORF7a targeted by             
Favipiravir). Based on this hypothesis (discussed in more detail in the Supplementary            
Material), we investigate the pathways connecting these viral proteins with the two effective             
drugs Chloroquine and Favipiravir. To this end, we select two known heme binding host              
proteins as seeds: Cytochrome b5 reductase, which interacts with the viral protein NSP7,             
and the viral ORF3a, which binds to Heme oxygenase 1 (HMOX1). Using KeyPathwayMiner             
for drug target discovery followed by Closeness Centrality for drug discovery, we identify             
methylene blue in addition to Chloroquine and Deferoxamine, which are both in COVID-19             
clinical trials ​44,45​. Notably, Methylene blue is approved by the FDA for the treatment of               
methemoglobinemia, which fits the investigated hypothesis (reduced oxygen-carrying        
capacity). Also, Deferoxamine is widely used therapeutically as a chelator of ferric ions in              
disorders of iron overload ​46​. However, note that the available scientific evidence for a              
methemoglobinemia or ferric ion imbalance caused by SARS-CoV-2 is very limited (see            
Supplementary Material) and that we use this hypothesis solely to illustrate the potential of              
CoVex’ network medicine investigation and hypothesis testing capabilities. 
Discussion 
COVID-19 is a threat to our health, our social life, as well as our healthcare and economic                 
systems around the globe. Since the development of safe and effective vaccines is a              
time-consuming process, the only alternative to mitigate the damage by the SARS-CoV-2            
pandemic is to quickly identify agents for the treatment and control of COVID-19 symptoms.              
Much attention in biomedical and clinical research is, thus, given to the task of identifying               
therapeutically exploitable drugs. A particular interest lies in drug repurposing, since already            
approved drugs can go through shortened clinical trials within months rather than years.             
While a number of promising drug repurposing candidates are currently being tested, the             
discovery of such candidates is still unstandardized and mostly unstructured. Systems and            
network medicine offer alternative approaches, where the process of drug target discovery is             
driven by computational data mining methods utilizing molecular interaction networks. As           
 recently demonstrated by Gysi ​et al. for SARS-CoV-2, this data-driven process can produce             
a list of promising drug candidates targeting host proteins in close proximity and             
mechanistically related to virus-interacting proteins ​11​. Here, we seek to make this network             
medicine approach widely available to the community. 
 
With CoVex, we present an interactive and user-friendly web platform that integrates            
published data of SARS-CoV-1 as well as recent data about virus-host interactions in             
SARS-CoV-2 ​10 with the human interactome and several drug-target interaction databases.           
CoVex allows users to mine the integrated virus-host-drug interactome for promising drug            
targets and drug repurposing candidates with only a few mouse clicks. Through features             
such as interactive seed protein selection, filtering and upload of own lists of proteins or               
drugs of interest, CoVex covers diverse application scenarios ranging from data-driven,           
hypothesis-free drug target discovery to expert-guided analyses with a clear underlying           
hypothesis about virus biology. To address the diversity of research questions adequately,            
CoVex implements several state-of-the-art graph analysis methods. These were specifically          
tailored to be employed in a network medicine context and include a weighted version of               
TrustRank as well as a novel multi-Steiner tree method (Supplementary Material). 
 
While CoVex is a powerful tool for SARS-CoV-1 and -2 research, results uncovered with our               
platform have to be considered with caution. We stress that the suggested drug candidates              
need to be properly vetted by clinical experts and tested following established procedures             
and clinical trials. Current data about virus-host interactions in SARS-CoV-2 is still            
preliminary and incomplete. For instance, important proteins such as the ACE2 receptor, a             
known entrypoint for the virus ​35​, is missing in the SARS-CoV-2 dataset by Gordon ​et al. ​10​.                 
Moreover, we included only drugs that are reported in databases about clinical trials or in the                
literature if they have a valid entry in DrugBank, possibly excluding some of the drugs               
currently being investigated. Further, we do not differentiate between different sources of            
drug target interactions. The strength of experimental evidence may vary depending on the             
experimental assay that was used or the type of annotation from the source database, e.g.               
clinical annotations and variant annotations from PharmGKB which can be interpreted as            
indirect drug-protein associations. It should also be noted that we do not list drugs that target                
viral proteins directly, as the goal of CoVex is to unravel novel drug targets further               
downstream in the human interactome.  
 
We acknowledge that the choice of algorithm and its associated parameters is non-trivial,             
forcing users to engage in time-consuming explorative analysis. To make this easier, we             
allow users to queue multiple tasks, which are executed in parallel. As our experience with               
this platform grows, we also plan to develop guidelines that allow users to choose an               
appropriate method for a particular research question. We further plan to integrate new data              
about virus-host interactions and ongoing clinical trials in corona viruses as it becomes             
available. 
 
For the future, we also plan to extend the CoVex network medicine platform to other viruses                
in which new drug targets and drug repurposing candidates are urgently sought, including             
MERS, Zika, influenza and dengue. 
 Conclusions  
We present CoVex, the first web-based platform for the interactive exploration and            
network-based analysis of virus-host interactions, aimed towards drug repurposing for the           
treatment of COVID-19. CoVex can be easily updated to accommodate the fast-paced data             
generation in the battle against the global pandemic. CoVex is expected to speed up the               
discovery of potential therapeutics for COVID-19. 
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 Supplementary Material - Exploring the SARS-CoV-2 virus-host-drug interactome for drug 
repurposing 
 
Here, we present the new algorithmic techniques we developed to analyze the virus-host-drug             
interactome by starting from a set of seed nodes, avoiding hubs. Moreover, we give additional,               
detailed information about the application cases described in our CoVex paper.  
 
New models and algorithms for seeded, weighted network analysis with hub-penalties 
 
Multi-Steiner trees: The Steiner tree problem is a classical combinatorial optimization problem.            
Given an undirected graph with non-negative edge costs and a set of seed nodes    V , )G = ( E      c        
, it asks to compute a minimum-cost Steiner tree for , where a Steiner tree for is aS ⊆ V           S       S    
tree in that contains all nodes . Exactly solving this problem is NP-hard, but several  G      v ∈ S          
efficient approximation algorithms exist. 
 
In CoVex, we compute (several) Steiner trees to connect selected host or viral proteins and               
extract a potentially druggable mechanism. For this, we developed a customized version of the              
2-approximation algorithm by Kou et al. ​1,2​. There are two main differences: First, we do not only                 
compute one but return the union of Steiner trees, where is a parameter that can be set       K     K         
by the user. Computing several Steiner trees increases the stability of the extracted mechanism.              
This is important, because the networks used in CoVex are very dense, which implies that               
solutions to the Steiner tree problem are usually non-unique. Which solution is returned is,              
hence, a matter of chance, if only one Steiner tree is computed. Returning the union of                K  
Steiner trees mitigates this problem. Second, we employ special parameterized edge costs             c λ  
with a hub-penalty that can be specified by the user (detailed below). If is set to a   0, ]λ∈ [ 1           λ      
value close to 1, the returned Steiner trees avoid hub-nodes. This is important, because              
targeting proteins which are hub-nodes in the human protein-protein interaction (PPI) network            
potentially results in many undesired side effects. 
 
The multi-Steiner tree algorithm employed in CoVex is implemented as follows: In a first step,               
we use the algorithm by Kou et al. to compute the first Steiner tree . Moreover, we run a              T      
depth-first search to find all bridges in the graph, where a bridge is an edge whose deletion                 
results in the graph being disconnected. Let be the list of edges in , be the cost of ,       L        T  C      T  
and be a user defined tolerance that specifies by how much the costs of the subsequent trees τ                  
may exceed . Furthermore, let be the number of already discovered trees (initialized to 1)  C    k            
and be the set of returned nodes (initialized to the nodes contained in ). We iterate the U              T     
following steps until  or  is empty. Subsequently, we return the subgraph induced by .k = K L U  
 
1. Pop edge  from .e L  
2. If  is a bridge, go to step 1.e  
3. Temporarily delete  from .e G  
 4. Run the algorithm by Kou et al. to compute the next candidate tree .T ′  
5. If the cost of  does not exceed , add the nodes of  to and increment .T ′ C · 100
100 + τ T ′ U  k  
6. Remove all edges from  which are not contained in .L T ′  
7. Reinsert  into .e G  
 
Weighted TrustRank​: TrustRank is a variant of Google’s pagerank algorithm, where “trust” is             
iteratively propagated through the network starting from an initial set of (trusted) seed nodes ​3​.               
At termination, each node in the network receives a score which is high if the node is easily                  
reachable from a subset of seed nodes, which themselves assume central positions in the              
overall topology of the network. 
 
In CoVex, TrustRank can be used for two purposes. First, TrustRank can be used to rank drugs                 
targeting a previously selected or computed set of host proteins. Second, it can be employed to                
discover potentially druggable host proteins which are relevant for a given set of viral or host                
seed proteins. Note that, unlike the result returned by the multi-Steiner algorithm, the top ranked               
nodes returned by TrustRank are not guaranteed to be connected. In practice, however, many              
of the returned nodes often form one large connected component. Thus, TrustRank allows to              
extract pathways in situations where it is not clear ​a priori ​that all seed nodes are involved in                  
one mechanism. 
 
In CoVex, we use a customized version of the TrustRank algorithm which allows the user to                
avoid hubs, if required. This is achieved by defining parameterized edge diameters            
(the definition of is given below in section “Parameterized edge costs with (e) /c (e)d λ = 1 λ     c λ           
hub-penalty”). If the user sets the hub-penalty to a value close to 1, the diameters of the       λ            
edges which are incident with hub-nodes are small. Therefore, “trust” flows less easily to the               
hubs, which implies that they obtain a lower score. Further parameters are the result size, which                
specifies how many top ranked nodes should be displayed in the result, and the damping factor                
. The damping factor controls how easily “trust” can flow to nodes which are far0, ]d∈ [ 1     d             
away from the seeds. The larger , the higher scores distant nodes receive.d  
 
Weighted, seeded closeness centrality: ​Closeness centrality is a simple centrality measure           
which ranks the nodes in a network based on the average distance of the shortest paths to all                  
other nodes. Kacprowski et al. suggested a version of this centrality measure where only the               
distances to a selected set of seed nodes are taken into consideration ​4​.  
 
In CoVex, we use a modified version of this approach which uses the parameterized edge costs                
instead of uniform costs. This customized version of seeded closeness centrality hence c λ              
assigns lower scores to hubs, if requested by the user. Like TrustRank, closeness centrality can               
be used both for extracting drug targets and for ranking drugs. 
 
Parameterized edge costs with hub-penalty: For each edge in the network , the        u, )( v ∈ E     G   
parameterized costs employed by the three algorithms presented above are defined as            
 , where and are the degrees (i.e., (u, ) 1 ) vdeg(G) λc λ v = ( − λ · a +  · 2
deg(u) + deg(v)   eg(u)d   eg(v)d      
number of links) of the nodes and , is the mean degree of all nodes contained in      u   v  vdeg(G)a           
, and is a hub-penalty, which can be specified by the user. Note that for , allG   0, ]λ∈ [ 1               λ = 0   
edge costs equal (no hub-penalty), while for , the cost of each edge is a direct   vdeg(G)a      λ = 1          
function of the degrees of its incident nodes (maximal hub-penalty). By setting to a value            λ     
between 0 and 1, the user can balance between these two extremes. 
 
 
Figure S1 - The multi-Steiner tree connecting all host proteins​ interacting with the virus 
(blue nodes are seeds) visualized in Cytoscape ​5​ using the GraphML export feature of CoVex. 
The purple nodes are the connectors building a tree structured subnetwork of the human 
interactome. 
 
Why the host protein interactions matter for drug repurposing 
 
 247 out of 332 ​host proteins interacting with the virus (interactors) reported in Gordon ​et al. ​6 for                  
SARS-CoV-2 form a large connected component, indicating that most of the direct targets of the               
virus are in a close proximity in the human interactome. 12 drugs currently in clinical trials                
(Dexamethasone, Colchicine, Pravastatin, Ribavirin, Ruxolitinib, Bromhexine, Oseltamivir,       
Noscapine, Ascorbic acid, Tofacitinib, Artenimol, Suramin) target the virus interactors directly.           
Figure S1 shows a Steiner tree of minimum cost connecting all the interactors. It consists of 44                 
connector proteins in addition to 332 interactors. The Steiner tree enables us to find new drug                
target candidates. Importantly, six of the 69 drugs currently in clinical trials (Table S5) target               
exclusively the connector proteins revealed by our analysis, namely Glycyrrhizic acid, Synthetic            
Conjugated Estrogens B, Leflunomide, Chloroquine, Deferoxamine, and Thalidomide. 
 
The four application scenarios 
 
Application scenario a - Starting from a selection of viral proteins, we seek to use the human                 
interactome to identify biological mechanisms or pathways utilized by the virus during infection.             
As an example, we are interested in the viral proteins E, M and Spike, which constitute the                 
external structure of the virus and thus participate in the entry into host cells ​7,8​.  
 
First, we select all host proteins interacting with the viral proteins E, M and Spike from the                 
SARS-CoV-2 dataset. We then use the multi-Steiner Tree algorithm with the parameters shown             
in Table S1 to uncover the biological pathway involved. The resulting network allows the              
identification of 26 new potential drug targets, including the Bradykinin receptor B1 (BDKRB1).  
 
Next, we use closeness centrality with the parameters shown in Table S1 to find drugs affecting                
this pathway. We identify a total of 30 approved and 10 non-approved drugs (Figure S2).               
Notably, we find 6 relevant drugs that target BDKRB1: Ramipril, Captopril, Perindopril and             
Enalaprilat (approved), which belong to the Angiotensin Converting Enzyme (ACE) inhibitor           
class ​9​. Icatibant is an antagonist of the Bradykinin receptor B2 ​10 and bradykinin is a                
non-approved drug which is degraded by the ACE ​11​.  
 
Finally, to understand the relationship between BDKRB1 and Angiotensin Converting Enzyme 2            
(ACE2) as well as Transmembrane protease serine 2 (TMPRSS2), two proteins known to be              
involved during virus entry ​12​, we use the “custom proteins” option available in CoVex and utilize                
the multi-Steiner tree algorithm with the same parameters as in Table S1. We find that the                
Kininogen 1 (KNG1) and Angiotensin (AGT) proteins connect BDKRB1 with ACE2 (Figure S3).             
These 4 proteins are functionally related through the Renin-Angiotensin System, which is            
targeted by ACE inhibitors (​https://www.wikipathways.org/instance/WP554​).  
 
In summary, CoVex identifies the protein BDKRB1, which participates in the pathway affected             
by SARS-CoV-2 and can be targeted by several ACE inhibitors, which are widely used in clinical                
trials to treat COVID-19. It should be noted that the ACE2 protein is not present in the set of                   
seeds used to start the analysis; however, CoVex is capable of identifying the pathway and new                
protein targets functionally related to ACE2, which can be targeted by ACE inhibitors as well. In                
 this case, CoVex allows the identification of the mechanism behind the drugs currently             
considered for treating currently considered for treating COVID-19. 
 
Figure S2 - Network obtained from interactors of baits E, M and Spike with multi-Steiner 
tree followed by closeness centrality.​ Blue nodes are protein targets, green nodes are 
approved drugs and orange nodes are non-approved drugs. Lines represent the interactions 
between the proteins and drugs. ACE inhibitor drugs are identified, such as Ramipril, Captopril, 
Perindopril and Enalaprilat targeting the BDKRB1 protein, which are currently being evaluated in 
clinical trials in COVID-19 patients. Note that we also included this Figure in the main document 
(Figure 4) to showcase how CoVex results look like but kept it here as well for increased 
readability. 
 
 
 
Figure S3 - The subnetwork obtained with the multi-Steiner tree algorithm shows the 
connections between ACE2, TMPRSS2 and BDKRB1.​ Dark blue nodes represent the seed 
proteins and light blue nodes represent the connector proteins identified. 
 
Table S1 - Algorithms and parameters used in application scenario a 
 Algorithm 
  multi-Steiner tree Closeness centrality 
Number of trees 10 N.A. 
Tolerance 0 N.A. 
Result size N.A. 40 
Maximum degree DISABLED DISABLED 
Hub penalty 0 1 
Include non-seed viral proteins FALSE N.A. 
Include indirect drugs N.A. FALSE 
Include non-approved drugs N.A. TRUE 
 
Application scenario b - Candidate drugs for the treatment of COVID-19 can be identified              
starting from a user-defined set of seeds comprising differentially expressed genes (DEGs) and             
viral proteins. Such a custom list can be obtained from other datasets, such as experiments               
and/or literature. One possible strategy is to use proteins known to be associated with a specific                
biological process, such as SARS-CoV-2 proteins involved in viral pathogenesis and host            
proteins that participate in the corresponding host immune response to infection. This way, we              
use the host PPI network to connect the viral proteins to the DEGs and obtain a potential                 
mechanism that can be targeted using repurposable drugs. To obtain a custom list of DEGs,               
raw counts from the gene expression data of SARS-CoV-2-infected lung epithelial A549 cells             
relative to mock-treated cells were obtained from Blanco-Melo ​et al. ​13 (GEO accession             
GSE147507). Differential expression analysis using the edgeR (v.3.26.8) package (fold change           
≥​2, adjusted p-value <0.05) was performed to obtain a list of DEGs. To identify host cell                
pathways enriched in response to SARS-CoV-2 infection, KEGG enrichment was performed           
using the gseapy (​v.0.9.15​) ​package. Enriched KEGG terms included pathways that are known             
to be involved in immune response to pathogens, such as “Influenza A”, “Herpes simplex              
infection”, “Measles”, and “Hepatitis C”. 
 
In this example, we use the CoVex platform to select viral proteins involved in innate immune                
response and apoptosis, namely, ORF7a and ORF3a, as indicated in Gordon ​et al. ​6​. Next,               
using the “Custom proteins” option, we upload the Uniprot IDs of the DEGs that participate in                
the enriched pathway Herpes simplex infection, which is involved in response to infection with              
Herpes simplex virus (HSV), another viral pathogen. The enriched DEGs include ​IFIH1​, ​OAS1​,             
STAT1​, ​DDX58​, ​OAS2​, ​OAS3​, ​IRF7​, ​EIF2AK2​, ​IFIT1​, and ​IRF9​. We then use both the viral               
proteins and DEGs as seeds for the multi-Steiner tree algorithm to extract a subnetwork that is                
relevant to our pathway of interest, shown in Figure S4. Next, we use closeness centrality on                
the resulting subnetwork to obtain drugs. The parameters used to run the multi-Steiner tree and               
closeness centrality algorithms can be found in Table S2. Top-ranking drugs included Tofacitinib             
and Ruxolitinib, which are currently being assessed in clinical trials for the treatment of              
COVID-19 (Figure S5). Tofacitinib and Ruxolitinib are both known to inhibit Janus kinase (Jak),              
which promote cytokine signaling ​14,15​. Thus, administration with these drugs can mitigate            
immune-mediated ​lung ​injury and prevent functional functional deterioration in COVID-19           
 patients caused by an over-amplified host immune response. As shown in Figure S5, other              
drugs that target this subnetwork include Masitinib, Erlotinib, and Sorafenib, which could be             
further examined in downstream analyses. In a similar manner, users can provide a custom list               
of proteins to retrieve drugs that can target their mechanism of interest, followed by careful               
examination of the results. 
 
Table S2 - Algorithms and parameters used in application scenario b 
 Algorithm 
 multi-Steiner tree Closeness centrality 
Number of trees 10 N.A. 
Tolerance 0 N.A. 
Result size N.A. 20 
Maximum degree DISABLED DISABLED 
Hub penalty 0 0 
Include non-seed viral proteins TRUE N.A. 
Include indirect drugs N.A. FALSE 
Include non-approved drugs N.A. FALSE 
 
 
Figure S4 - The subnetwork showing the connections between the viral proteins (ORF7A, 
ORF3A) and proteins involved in Herpes simplex infection.​ Dark blue nodes indicate 
proteins involved in Herpes simplex infection, while bright blue nodes indicate the connector 
nodes found by the multi-Steiner tree algorithm. The resulting subnetwork comprises potential 
drug targets to suppress the host immune response. 
  
Figure S5 - Closeness centrality recovered drugs​, such as Tofacitinib and Ruxolitinib, which 
are currently being evaluated in clinical trials in COVID-19 patients. 
 
Application scenario c - Another approach to find candidate drugs to combat COVID-19 is to               
connect the targets of promising drugs which are already in clinical trials to the viral proteins.                
We can identify the candidate mechanisms by extracting the sub-network(s) connecting these            
two ends with a minimum number of intermediate connector proteins. This step can be done by                
using the multi-Steiner tree algorithm integrated in our CoVex platform. We can then seek for               
the drugs targeting the identified connector proteins utilizing the closeness centrality algorithm            
from the “Find Drugs” function.  
 
As an example, we start with the drugs classified as immunostimulants (Sargramostim,            
Peginterferon beta-1a, and Peginterferon alfa-2a)​16​, and then use the multi-Steiner tree           
algorithm from the “Find Drug Targets” function to connect their targets (IL3RA, CSF2RB,             
SDC2, PRG2, IFNAR2, IFNAR1, and CSF2RA) to the host interactor genes of viral proteins              
ORF9B, ORF6, ORF3B, and ORF3A (ALG5, ARL6IP6, BAG5, CHMP2A, CLCC1, CSDE1,           
DCTPP1, DPH5, HEATR3, HMOX1, MARK1, MARK2, MARK3, MDN1, MTCH1, NUP98,          
PTBP2, RAE1, SLC9A3R1, STOML2, SUN2, TOMM70, TRIM59, VPS11, VPS39), see Figure           
S6. Among the identified connector proteins, we find five genes (CSF2, NRG1, NUP188,             
PTPN18, SOCS1) associated with cytokine signaling in the immune system according to            
Reactome Pathways ​17​. From this list, notably, CSF2 is enriched in lung and immune cells               
(​www.proteinatlas.org/ENSG00000164400-CSF2​) ​18​. This gene can be inhibited by the         
investigational drug ​KB002 (​DB05194) (Figure S7), which is an engineered human monoclonal            
antibody-based treatment for inflammatory and autoimmune processes ​19​. 
 
 Table S3 - Algorithms and parameters used in application scenario c 
 
 Algorithm 
 multi-Steiner tree Closeness centrality 
Number of trees 10 N.A. 
Tolerance 0 N.A. 
Result size N.A. 50 
Maximum degree DISABLED DISABLED 
Hub penalty 1 0 
Include non-seed viral proteins FALSE N.A. 
Include indirect drugs N.A. FALSE 
Include non-approved drugs N.A. TRUE 
  
 
Figure S6 - Cytoscape illustration of the multi-Steiner tree​ analysis performed with CoVex 
after using the export to GraphML feature, with targets of Sargramostim, Peginterferon beta-1a, 
and Peginterferon alfa-2a (purple) and the host interactor genes of viral proteins ORF9B, ORF6, 
ORF3B, and ORF3A (green) as seeds. Connector proteins (blue). Viral proteins (red). 
Connector genes associated with cytokine signaling in the immune system (circled in blue). 
 
  
Figure S7 - The closeness centrality algorithms ranks the drugs​ targeting the connector 
nodes from Figure S6. The protein encoded by CSF2 is inhibited by drug ​KB002 (​DB05194). 
 
Application scenario d - Some hypotheses might require a hybrid seeding approach, where             
we are required to start from a hypothesis-driven mixed selection of viral and host proteins as                
well as drugs to explore protein-protein interactions to identify a mechanism and suggest             
additional drugs. 
 
Here, we follow a recently published hypothesis concerning the interference of the SARS-CoV-2             
with the formation of hemoglobin in erythrocytes ​22,23​. Essentially, we follow the idea that the               
virus could interfere with porphyrin, which is a substrate, together with iron (Fe​2+​) ions, during               
the synthesis of the heme prosthetic group in hemoglobin. The viral proteins thus hinder the               
interaction of iron with porphyrin, as the viral proteins are hypothesized to compete with iron for                
the porphyrin and thus to inhibit heme group synthesis, leading to hypoxia symptoms ​24​. Liu and                
Abrahams suggest that this might explain why Chloroquine and Favipiravir are effective drugs,             
as they may prevent the virus from competing with iron for the porphyrin: Chloroquine by               
interfering with the viral proteins NSP1-16, ORF3a, and ORF10 which may bind the porphyrin to               
prevent heme synthesis, and also by inhibiting the binding of viral protein ORF8 to porphyrins               
“to a certain extent” ​24​. Favipiravir could prohibit ORF7a from binding to (free) porphyrin in               
addition to preventing the virus from entering the host cells ​24​. 
 
 Starting from this theory, we investigate the host interactome for potential drug repurposing             
candidates. In CoVex, we selected the viral proteins NSP1-16, ORF3a, ORF7a, ORF8 and             
ORF10 as seeds and expanded the network to all of their host partner proteins. Notably, we see                 
that NSP7 may bind to Cytochrome b5 reductase (CYB5R), which converts methemoglobin to             
hemoglobin (oxygen-transporting Fe​2+ hemoglobin to non-oxygen-transporting Fe​3+       
hemoglobin). Cytochrome b5 reductase is involved in the transfer of reducing equivalents from             
the physiological electron donor, NADH, via an FAD domain to the small molecules of              
cytochrome b5. It is also heavily involved in many oxidation and reduction reactions, such as the                
reduction of methemoglobin to hemoglobin ​25–27​. In addition, we see that ORF3a binds to              
HMOX1 (Heme oxygenase 1), which might lead to interference with heme degradation. We             
continued with all 238 host interactors as new seeds and executed KeyPathwayMiner (Table             
S4) to investigate the host interactome for proteins that connect the selected virus-host             
interactions proteins. We discovered five new drug targets (the proteins APP, XPO1, TRIM25,             
HSCB, FBXO6) for which we extracted 20 drug candidates using the closeness centrality             
measure and only screening for currently approved drugs. In the resulting ranked list, we              
rediscovered Chloroquine as well as Deferoxamine, both of which are currently in clinical trial or               
discussed in the literature as candidate drugs for COVID-19 treatment. Note that Deferoxamine             
is widely used for the treatment of Thalassemia and as a chelator of ferric ion in disorders of                  
iron overload ​28​. In addition to these two drugs, we find Methylene blue, a drug that is approved                  
by the FDA for the treatment of methemoglobinemia. Note that the evidence for a              
methemoglobinemia caused by SARS-CoV-2 is anecdotal (no reports on abnormal          
methemoglobin levels, iron metabolism markers, etc. exist) and we used this hypothesis to             
illustrate a potential hybrid level starting point for the network medicine investigation of a              
hypothesis using CoVex. 
 
Table S4 - Algorithms and parameters used in application scenario d 
 
 Algorithm 
 KeyPathwayMiner Closeness centrality 
K 5 N.A. 
Result Size N.A. 20 
Maximum Degree N.A. DISABLED 
Hub Penalty N.A. 0.5 
Include indirect drugs N.A. FALSE 
Include non-approved drugs N.A. FALSE 
 
 
Table S5 - All drugs in clinical trials targeting host proteins sorted by classification.​ We 
compiled a list of all drugs targeting human proteins currently registered in clinical governmental 
trial databases (see full paper). 
 
 Drug Classification Class ID Drug names 
Immunostimulants L03  Sargramostim,Peginterferon alfa-2a,Peginterferon beta-1a 
Immunosuppressants L04  Eculizumab,Thalidomide,Pirfenidone,Anakinra,Fingolimod,Tocil
izumab,Sarilumab, 
Ixekizumab,Siltuximab,Leflunomide,Emapalumab,Tofacitinib,A
dalimumab,Baricitinib 
Antineoplastic agents L01  Ruxolitinib,Bevacizumab 
Gynecological Anti Infectives And 
Antiseptics 
G01  Darunavir,Ascorbic acid,Sildenafil 
Vitamins A11  Calcitriol,Ascorbic acid 
Ophthalmologicals S01  Heparin,Dexamethasone,Acetylcysteine,Ascorbic 
acid,Methylprednisolone,Azithromycin 
Antipsoriatics D05  Calcitriol 
Lipid Modifying Agents C10  Pravastatin 
Antiobesity Preparations;excl.Diet 
Products 
A08  Phentermine 
Antivirals For Systemic Use J05  Atazanavir,Ribavirin,Oseltamivir,Cobicistat,Sofosbuvir,Ritonavir
,Darunavir,Lopinavir 
Urologicals G04  Sildenafil 
Antibacterials For Systemic Use J01  Azithromycin 
Other Respiratory System Products R07  Nitric Oxide 
Antiprotozoals P01  Suramin,Hydroxychloroquine,Artenimol,Chloroquine 
Psycholeptics N05  Dexmedetomidine 
Agents Acting On The Renin-angiotensin 
system 
C09  Losartan 
Allothertherapeuticproducts V03  Oxygen,Deferoxamine,Acetylcysteine,Cobicistat 
Other Gynecologicals G02  Naproxen 
Topical Products For Joint And Muscular 
Pain 
M02  Naproxen 
Anti Inflammatory And Antirheumatic 
Products 
M01  Naproxen 
Anesthetics N01  Sevoflurane,Propofol 
Anthelmintics P02  Levamisole 
Anti-acne preparations D10  Dexamethasone,Methylprednisolone 
 Corticosteroids For Systemic Use H02  Dexamethasone,Methylprednisolone 
Corticosteroids;dermatological 
preparations 
D07  Dexamethasone,Methylprednisolone 
Antithromboticagents B01  Heparin,Enoxaparin,Dipyridamole 
Vasoprotectives C05  Heparin,Dexamethasone 
Nasal Preparations R01  Ciclesonide,Dexamethasone 
Ophthalmological And Cytological 
Preparations 
S03  Dexamethasone 
Otologicals S02  Dexamethasone 
Stomatological Preparations A01  Dexamethasone 
Antigout Preparations M04  Colchicine 
Drugs for obstructive airway diseases R03  Ciclesonide,Mepolizumab 
Coughandcoldpreparations R05  Acetylcysteine,Bromhexine,Noscapine 
Cardiac therapy C01  Angiotensin II 
Anti Hemorrhagic B02  Camostat 
Bile And Liver Therapy A05  Glycyrrhizic acid 
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